biotech
biotech Articles
SunTrust Robinson Humphrey has issued a new Buy rating Compugen, and the firm's target price represents more than 100% in implied upside from the prior close.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this coronavirus and here is where their stocks stand now.
Published:
GenMark Diagnostics stock has really not made any of the zany exponential gains that have been seen in other coronavirus-related stocks.
Published:
Aytu BioScience was largely unknown until it announced that it had a test for COVID-19. Since then, it has seen a meteoric rise in its common stock price. Does the future look bright?
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine, treatment or test to deal with this novel coronavirus. Here's how they fared as the week wound down.
Published:
GenMark Diagnostics stock shot up on Friday after the company announced that the FDA has issued an Emergency Use Authorization for the company’s ePlex SARS-CoV-2 test.
Published:
Amarin has been right in the middle of this recent market sell-off, and while shares have been halved, the stock could be poised for a strong recovery. All the pieces seem to be there.
Published:
24/7 Wall St. has tracked some health care companies with prospects at crafting a vaccine to deal with this novel coronavirus and where they stand now.
Published:
BioNTech stock jumped on Tuesday and went even higher early on Wednesday. This comes after the company announced a collaboration with the pharmaceutical giant Pfizer.
Published:
Like all developmental drug companies, Bio-Path is betting on the success of its drug candidates. Drugs that are in trials often fail, so investors need to gamble that one or more of its treatments...
Published:
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
Published:
It is not a new scenario where an illness or problem starts to become a big deal in the public and there is a small-cap company that “has a solution for that” which happen to be known by very few...
Published:
More and more companies are joining the fight against the coronavirus, and 24/7 Wall St. is taking a look at some of the biggest movers on the day tied to COVID-19.
Published:
Kala Pharmaceuticals said that it had positive topline results from its late-stage clinical trial for the treatment of dry eye disease.
Published:
Shares of Amarin have plunged in recent months. Even more troubling, there appears to no catalyst to drive them higher.
Published: